North America Breast Cancer Therapeutics Market size surpassed USD 9.9 billion in 2021 and is anticipated to exhibit around 7.4% CAGR from 2022 to 2028.

The increasing prevalence of breast cancer in the region is expected to proliferate the North America market growth significantly. According to the Breast Cancer.org 2021 statistics, breast cancer is amongst the most prevalent form of cancer among American women. The estimates suggest that in 2022, approximately 30% of newly diagnosed cancers among women are expected to be breast cancer cases. As of January 2022, over 3.8 million women in the U.S. are suffering from breast cancer. Also, around 1 in 8 women (around 13%) in the U.S. are expected to be diagnosed with invasive breast cancer over the course of their lifetime. The surging prevalence and substantial incidence rates of the disease are anticipated to promote the demand for breast cancer therapeutics. Further, the disease inflicts substantial disease and financial burden on the healthcare systems.

Get more details on this report - Request Free Sample PDF

The increasing awareness regarding breast cancer owing to supportive initiatives launched in the region will encourage the patients to undergo therapeutics. For instance, the Center for Disease Control and Prevention (CDC) collaborates with public, private, and non-profit organizations to educate people regarding breast cancer through a variety of activities. The Our Bring Your Brave program offers knowledge concerning breast cancer to women. Further, the Advisory Committee on Breast Cancer in Young Women, provides guidance concerning advancement, implementation, and assessment of evidence-sourced activities targeting prevention, early detection, and survivorship of breast cancer. The Cancer Genomics Program innovates optimal practices in education, surveillance, and reinstates an evidence base for the utilization of cancer genomics in public health practice.

North America Market, By Therapy

The targeted therapy segment will showcase 7.8% growth rate during the forecast period. Breast cancer targeted therapies employ medications that inhibit the growth of cancerous cells by interfering with the tumor cell proliferation. Owing to the recent advancements in molecular biology and immunotherapy, very precise targeted therapies have been developed to target the specific pathophysiology of breast cancer. These ongoing advancements have contributed to develop a more target specific and efficient therapeutic protocol in breast cancer patients.

Several targeted therapies are commercially available for application in cancer treatment such as gene expression modulators, signal transduction inhibitors, angiogenesis inhibitors, apoptosis inducers, and toxin delivery molecules. These therapies are currently emphasized for anticancer drug development and are being increasingly used in precision medicine.

North America Market, By Country

U.S. breast cancer therapeutics market accounted over USD 9.3 billion revenue in 2021. This large market size is attributed to the rising prevalence of breast cancer, incremental cancer care expenditure, and facilitative reimbursement scenario in the country. etc.

As per the U.S. Breast Cancer Statistics 2022, an estimated 287,850 new cases of invasive breast cancer are projected to be detected among the U.S. women, along with 51,400 new cases of non-invasive (in situ) breast cancer. Further, approximately 43,250 women are estimated to die in 2022 pertaining to breast cancer. Owing to such high prevalence rates, the government expenditure concerning cancer care is rising.

Competitive Industry Landscape

Prominent industry participants operating across the North America include AstraZeneca, Eli Lilly, & Co., Pfizer, BMS, Novartis, Amgen, Roche, and Merck. These major companies are adopting various organic and inorganic strategies such as product launches and partnerships for garnering maximum market share and strengthening their presence.